{"id":"clover-scb-2019","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SCB-2019 uses a recombinant trimeric spike protein platform to stimulate both cellular and humoral immunity against COVID-19. The vaccine is administered with an adjuvant to enhance immunogenicity and protective efficacy. This approach aims to generate durable antibody and T-cell responses against the coronavirus.","oneSentence":"Clover SCB-2019 is a recombinant protein vaccine candidate designed to elicit immune responses against SARS-CoV-2 by presenting stabilized spike protein trimers.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:06:28.118Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 prevention (SARS-CoV-2 infection)"}]},"trialDetails":[{"nctId":"NCT05228314","phase":"PHASE1","title":"Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults","status":"COMPLETED","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2022-05-30","conditions":"COVID-19","enrollment":153},{"nctId":"NCT05812586","phase":"PHASE3","title":"Assessment of Immunogenicity, Safety and Reactogenicity of a Booster Dose of Various COVID-19 Vaccine Platforms in Individuals Primed With Several Regimes.","status":"UNKNOWN","sponsor":"D'Or Institute for Research and Education","startDate":"2023-03-14","conditions":"COVID-19","enrollment":760},{"nctId":"NCT05470803","phase":"PHASE3","title":"An Observer-blind, Cohort Randomized, Exploratory Phase 3 Study to Evaluate the Safety and Immunogenicity of Recombinant Covid-19 Vaccine, mRNA Covid-19 Vaccine and Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine as 4th Dose in Individuals Primed/ Boosted With Various Regimens","status":"UNKNOWN","sponsor":"D'Or Institute for Research and Education","startDate":"2022-08","conditions":"COVID-19","enrollment":360},{"nctId":"NCT05087368","phase":"PHASE2","title":"Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac or a Formulation of SCB-2019 (COVID-19)","status":"UNKNOWN","sponsor":"D'Or Institute for Research and Education","startDate":"2021-12-01","conditions":"Covid19","enrollment":520},{"nctId":"NCT04950751","phase":"PHASE2","title":"Immunogenicity and Safety of Adjuvanted SCB-2020S Vaccines in Adults","status":"WITHDRAWN","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2021-08","conditions":"COVID-19","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Clover SCB-2019","genericName":"Clover SCB-2019","companyName":"D'Or Institute for Research and Education","companyId":"d-or-institute-for-research-and-education","modality":"Biologic","firstApprovalDate":"","aiSummary":"Clover SCB-2019 is a vaccine candidate that has been studied in a Phase 2 clinical trial for its immunogenicity and safety in adults. The trial, NCT04950751, evaluated the vaccine in comparison to the ChAdOx1-S COVID-19 Vaccine (Fiocruz/Oxford-AstraZeneca) and CoronaVac (Sinovac Biotech) for COVID-19.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}